ArticleBMC psychiatry2025
Genome-wide association and DNA methylation analyses of SSRI treatment response in major depressive disorder.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DNA hypomethylation of theFrontiers in neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundSelective serotonin reuptake inhibitors (SSRIs) are first-line treatments for major depressive disorder (MDD); however, patient responses vary significantly. This study explored genetic and epigenetic factors linked to SSRI response to better understand this heterogeneity.
methodsWe performed a genome-wide association study (GWAS) in 852 MDD patients classified as SSRI responders or non-responders. A polygenic risk score (PRS) analysis was conducted to estimate the cumulative effect of common genetic variants. In a subset of 66 participants, genome-wide DNA methylation profiling was carried out using the Illumina Methylation EPIC array. Analyses included the identification of differentially methylated positions (DMPs) and regions (DMRs), as well as weighted gene co-methylation network analysis (WGCNA) and downstream pathway and protein–protein interaction (PPI) analyses.
resultsGWAS revealed several loci with suggestive associations, including intronic variants in SRCIN1 and NKAIN3, although none reached genome-wide significance. The PRS explained a small proportion of variance in SSRI response and did not yield statistically significant results. DNA methylation analysis identified nominally differentially methylated CpGs in genes involved in synaptic signaling and neurodevelopment (e.g., OLFM1, PTN, CACNB2, LHX6). In addition, WGCNA identified a co-methylation module that showed a trend-level association with SSRI response after adjustment for clinical covariates, and hub genes within this module were functionally linked to neuronal signaling in PPI network analysis.
conclusionsAlthough no single marker reached significance, the results suggest that synaptic plasticity and neurodevelopment may influence SSRI response. These genomic and epigenomic insights offer molecular clues that may inform future studies on the biological mechanisms underlying antidepressant response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.